Jardiance Hair and Skin Changes: What Empagliflozin Actually Does

Does Jardiance Cause Hair Loss?

No large trial has identified hair loss as a statistically significant adverse event of empagliflozin. The EMPA-REG OUTCOME trial, which enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease, did not list alopecia in its safety table [1]. The FDA prescribing label for Jardiance similarly omits hair thinning from any frequency tier of adverse reactions [2].

Why Patients Ask About Hair Loss

Patients on empagliflozin often take multiple concurrent medications. Metformin, which depletes vitamin B12 over time, and certain antihypertensives can contribute to telogen effluvium. A 2019 cohort analysis in JAMA Internal Medicine found that long-term metformin use was associated with B12 deficiency in roughly 6% of patients [3], and B12 deficiency is a recognized trigger for diffuse hair shedding.

Clinicians should perform a targeted medication reconciliation before attributing hair changes to Jardiance. Check TSH, ferritin, vitamin B12, and zinc before concluding that empagliflozin is the culprit.

What the Data Actually Show

In the pooled safety database from the four key empagliflozin trials summarized in the FDA label, alopecia appeared in the "not reported at a frequency distinguishable from placebo" category [2]. Spontaneous post-marketing case reports of hair loss exist in pharmacovigilance databases, but these are confounded reports without a control arm.

A 2021 disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) found no statistically elevated reporting odds ratio for alopecia with any approved SGLT2 inhibitor compared with the full FAERS background [4].

Genital Mycotic Infections: The Most Common Skin-Adjacent Event

Glucosuria is empagliflozin's mechanism and its main dermatologic liability. By blocking sodium-glucose cotransporter-2 in the proximal tubule, the drug delivers roughly 70 g of glucose per day into the urine [2]. That glucose-rich environment promotes Candida albicans overgrowth in the vulvovaginal and balanopreputial areas.

Incidence Figures From Controlled Trials

In EMPA-REG OUTCOME, vulvovaginal mycotic infections occurred in 6.4% of women on empagliflozin 10 mg and 6.4% on 25 mg, compared with 1.8% on placebo [1]. Male genital mycotic infections affected 3.1% of men on empagliflozin 10 mg versus 0.4% on placebo.

A pooled analysis of 12 randomized controlled trials (N=11,228) published in Diabetes Care confirmed that female genital mycotic infection risk was roughly four times higher with empagliflozin than with placebo (odds ratio 4.23, 95% CI 3.03 to 5.89, P<0.001) [5].

Clinical Presentation and Skin Findings

Vulvovaginal candidiasis from glucosuria typically presents as erythematous, moist skin with satellite lesions at the vulvar folds, associated with white cottage-cheese discharge and pruritus. In men, the glans and prepuce show erythema, scaling, and occasionally fissuring. These skin signs differ from those of sexually transmitted infections but can be mistaken for contact dermatitis.

First-line treatment is topical azole cream (clotrimazole 1% or miconazole 2%) for 7 days in most uncomplicated cases, per CDC sexually transmitted infections guidelines [6]. Patients who experience three or more episodes per year on empagliflozin may warrant dose reassessment or a switch to a different drug class.

Risk Factors That Increase Susceptibility

Prior history of vaginal yeast infection is the strongest predictor of recurrence on SGLT2 therapy. Uncircumcised men have a higher balanitis risk [1]. Immunosuppression, poorly controlled glucose (HbA1c above 9%), and chronic corticosteroid use each compound the baseline risk.

Fournier's Gangrene: The Rare but Serious Warning

In 2018, the FDA issued a Drug Safety Communication requiring a class-wide warning for all SGLT2 inhibitors after identifying 12 confirmed cases of Fournier's gangrene (necrotizing fasciitis of the genitalia and perineum) across the SGLT2 inhibitor class [7]. This warning applies to empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin.

What Fournier's Gangrene Looks Like

The early skin signs include localized swelling, erythema, and tenderness of the perineum or genitalia that progress rapidly to crepitus and skin necrosis. Fever and sepsis follow within hours to days if untreated. Because the condition is polymicrobial, it requires emergent surgical debridement plus broad-spectrum antibiotics.

The FDA noted that the 12 cases identified from 2013 to 2018 compared unfavorably with only 6 cases reported across all other antidiabetic drug classes during a 30-year period [7]. Clinicians prescribing any SGLT2 inhibitor should counsel patients to seek same-day care for any unexplained perineal pain, swelling, or fever.

Absolute Risk Perspective

Fournier's gangrene remains extremely rare in the general population (incidence roughly 1.6 per 100,000 person-years) [8]. The number of Jardiance prescriptions dispensed in the United States exceeded 20 million annually by 2023, making the absolute risk attributable to the drug very small. Still, rapid recognition can be life-saving, so the warning carries clinical weight disproportionate to its frequency.

Hypersensitivity Rashes and Allergic Skin Reactions

Hypersensitivity reactions to empagliflozin are uncommon. The FDA label lists urticaria and hypersensitivity as adverse reactions occurring in <1% of trial participants [2]. Angioedema has been reported in isolated cases.

Distinguishing Drug Rash From Incidental Rash

A morbilliform (measles-like) drug eruption typically appears 7 to 14 days after initiating a new medication and distributes symmetrically across the trunk before spreading to the extremities. Urticaria from empagliflozin hypersensitivity tends to appear within the first 72 hours and resolves after discontinuation.

Fixed drug eruptions and Stevens-Johnson syndrome have not been reported in phase III empagliflozin data, but both are theoretically possible with any small-molecule agent. Any patient who develops mucosal involvement, blistering, or skin detachment while on Jardiance should discontinue the drug immediately and be evaluated by dermatology.

Re-challenge Policy

Re-challenge after a confirmed hypersensitivity reaction is not recommended. A clinician evaluating a patient with rash on empagliflozin should document the morphology, timing of onset relative to the first dose, and response to antihistamines before making a class-switch decision. Dapagliflozin and canagliflozin share the gliflozin scaffold, so cross-reactivity is theoretically possible, though published cross-reactivity cases are rare.

Skin Changes Related to Metabolic Improvement

Empagliflozin's cardiovascular and metabolic benefits may produce secondary skin improvements in some patients, particularly those whose type 2 diabetes has been poorly controlled.

Acanthosis Nigricans

Acanthosis nigricans, the velvety hyperpigmented skin thickening at the neck and axillae associated with hyperinsulinemia, may lighten as insulin sensitivity improves with better glycemic control. There are no dedicated trials of empagliflozin's effect on acanthosis nigricans, but a 2020 review in the Journal of the American Academy of Dermatology noted that glycemic improvement by any means tends to reduce the severity of acanthosis nigricans over months to years [9].

Diabetic Dermopathy and Wound Healing

Shin spots (diabetic dermopathy) and impaired wound healing in type 2 diabetes reflect underlying microvascular disease. EMPA-REG OUTCOME demonstrated a 38% relative risk reduction in cardiovascular death and a 39% relative risk reduction in hospitalization for heart failure [1], suggesting meaningful improvements in end-organ perfusion over time. Whether those hemodynamic gains translate to measurable improvements in diabetic skin findings has not been studied in a prospective trial.

A Practical Framework for Assessing Skin Changes on Empagliflozin

Clinicians can organize dermatologic assessment into three tiers:

• Tier 1 (Common, expected). Genital mycotic infection. Treat topically, reinforce hygiene, reassess drug continuation only if recurrent.
• Tier 2 (Uncommon, monitor). Urticaria or morbilliform rash. Photograph, obtain allergy consultation, withhold the drug pending evaluation.
• Tier 3 (Rare, emergent). Perineal pain, erythema, crepitus, or fever. Discontinue immediately, send to the emergency department for surgical evaluation.

Urinary Tract Infections and Adjacent Skin Considerations

Urinary tract infections (UTIs) occur more often in women on SGLT2 inhibitors, though the effect is smaller than the mycotic infection signal. In EMPA-REG OUTCOME, UTI rates were 9.3% on empagliflozin 10 mg versus 8.0% on placebo in women, a difference that did not reach statistical significance [1].

Recurrent UTIs can cause periurethral skin irritation and excoriation, which patients may describe as a "skin rash." Distinguishing UTI-related irritation from primary dermatologic events requires urinalysis, urine culture, and direct inspection.

Upper UTI (pyelonephritis) and urosepsis, though rare, have been reported with SGLT2 inhibitor class use. The FDA label for empagliflozin includes a warning about serious urinary tract infections, and clinicians should advise patients to report dysuria or fever promptly [2].

Dry Skin and Dehydration-Related Changes

SGLT2 inhibitors produce osmotic diuresis by excreting glucose in urine. At therapeutic doses, empagliflozin causes a modest reduction in plasma volume estimated at approximately 200 to 400 mL in the first weeks of therapy [10]. For most patients, this does not produce clinically detectable dehydration.

When Dry Skin May Reflect Volume Depletion

Elderly patients (age 75 or older), those on loop diuretics, or patients with baseline estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2 may experience more pronounced volume contraction. Skin turgor loss, dry mucous membranes, and orthostatic hypotension are the cardinal signs. These patients may also notice dry, flaky skin that they attribute to Jardiance.

The EMPEROR-Reduced trial (N=3,730), which studied empagliflozin in heart failure with reduced ejection fraction, reported dizziness and hypotension in 10.1% of the empagliflozin group versus 7.3% placebo, consistent with volume effects [11]. Clinicians should review diuretic doses when initiating empagliflozin in volume-sensitive patients.

Practical Hydration Guidance

Patients should drink enough fluid to keep urine a pale yellow. A simple skin check: if the back of the hand when pinched takes more than 2 seconds to flatten, volume depletion may be contributing to dry skin. That clinical sign, though imperfect, provides an immediate bedside cue.

Special Populations: Skin Considerations

Older Adults

Skin in adults over 75 is thinner, heals more slowly, and is more susceptible to fungal intertrigo in skin folds. The EMPA-REG OUTCOME subgroup of patients 65 or older showed no excess serious skin adverse events, but the absolute risk of genital infections remains proportionally higher because older adults are more likely to be immunocompromised or have functional limitations affecting hygiene [1].

Patients With CKD

The FDA approved empagliflozin for chronic kidney disease in 2023, following data from the EMPA-KIDNEY trial (N=6,609), which showed a 28% relative risk reduction in kidney disease progression or cardiovascular death [12]. In patients with eGFR below 45, the glucosuric effect is attenuated, which may reduce the genital infection rate. However, CKD patients have impaired immune function, making any skin infection potentially more serious.

Patients With Prior Genital Infections

The EMPA-REG OUTCOME subgroup with prior history of genital mycotic infections had a recurrence rate approximately double that of naive patients [1]. These patients warrant a pretreatment discussion about prophylactic hygiene measures and a lower threshold for switching therapy after a first recurrence.

Monitoring and Patient Education Protocol

Genital hygiene education before starting empagliflozin reduces mycotic infection rates. A 2022 systematic review in Diabetes, Obesity and Metabolism found that hygiene counseling at initiation was associated with a 30 to 40% reduction in first-episode genital mycotic infections in observational cohorts of SGLT2 inhibitor users [13].

Key counseling points include: keeping the genital area clean and dry, wearing breathable cotton underwear, avoiding prolonged moisture after exercise, and reporting any itch, discharge, or skin redness promptly. For uncircumcised men, daily retraction and cleaning of the prepuce reduces balanopreputial candidiasis risk.

At each follow-up visit, a brief question about genital symptoms takes under 30 seconds and identifies the majority of mycotic infections before they become severe or require oral antifungals.